NCT05089617View on ClinicalTrials.gov

To Evaluate the Safety, Tolerability, and Pharmacokinetics of YG1699（Antidiabetic） in Healthy Chinese Sbjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 9, 2022

Primary Completion Date

August 12, 2022

Study Completion Date

August 12, 2022

Conditions

Diabetes Mellitus

Interventions

DRUG

YG1699

"YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~Drug: Placebo~Placebo is the same appearance as YG1699."

Trial Locations (1)

200092

Shanghai Xinhua Hospital, Shanghai

All Listed Sponsors

lead

Youngene Therapeutics Inc., Ltd.

INDUSTRY

NCT05089617 - To Evaluate the Safety, Tolerability, and Pharmacokinetics of YG1699（Antidiabetic） in Healthy Chinese Sbjects | Biotech Hunter | Biotech Hunter